# US 2012/0083532 A1 · Novel uses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2012/0083532 A1 - Document ID: US20120083532A1 - Status: Published application - Kind: A1 - Application number: 13/377,130 - Filed: 2010-06-11 - Published: 2012-04-05 - Earliest claimed: 2009-06-12 - Assignees: Nanyang Polytechnic - Inventors: Mark Richards; Chee Wee Phoon; Mun Kin Lee - Web page: https://patentgrep.com/patent/US20120083532A1 ## CPC - C07C 233/18: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 27/14: Decongestants or antiallergics - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/12: Antivirals - A61P 35/00: Antineoplastic agents - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - C07C 275/24: containing six-membered aromatic rings - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to the use of a compound represented by the general formula (I), and pharmaceutically acceptable salts thereof, wherein: n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, a thioether group, and an amino group, wherein at least two of R1 is a hydroxyl group, a thiol group or an amino group, with the proviso that wherein n is 2, R1 is not on the carbon-2 position and the carbon-5 position of the phenyl group; R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group; Z is an oxygen (O) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group; in the manufacture of a medicament for treating a patient in need of cell therapy. ## Claims ### Claim at position 1 1-92. (canceled) ### Claim 93 A method for removing undifferentiated stem cells or dedifferentiated stem cells from a sample comprising said cells, the method comprising administering to said cell sample an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, a thioether group and an amino group, wherein at least two of R1 is a hydroxyl group, a thiol group or an amino group, with the proviso that wherein n is 2, R1 is not on the carbon-2 position and the carbon-5 position of the phenyl group; R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group; Z is an oxygen (O) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group. ### Claim 94 (depends on 93) A method of claim 93, wherein said cell sample further comprises differentiated cells. ### Claim 95 (depends on 94) A method of claim 94, further comprising the step of culturing the differentiated cells to prepare a cell population comprising differentiated cells. ### Claim 96 (depends on 93) The method of claim 93, wherein said undifferentiated stem cells or dedifferentiated stem cells are selected from the group consisting of human embryonic stem cells (hESC), induced pluripotent stem cells (IPSC) and cancer stem cells (CSC). ### Claim 97 A method for the treatment of a patient in need of cell therapy, the method comprising administering to the patient an effective amount of a compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, wherein n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, a thioether group and an amino group, wherein at least two of R1 is a hydroxyl group, a thiol group or an amino group, with the proviso that wherein n is 2, R1 is not on the carbon-2 position and the carbon-5 position of the phenyl group; R2 and R3 are independently a methylene group or a nucleophile, with the proviso that at least one of R2 and R3 is a nucleophile group; Z is an oxygen (O) atom or sulfur (S) atom; T is hydrogen or an optionally substituted aliphatic group. ### Claim 98 (depends on 97) The method as claimed in claim 97, wherein n is 2. ### Claim 99 (depends on 97) The method as claimed in claim 97, wherein Z is an oxygen (O) atom. ### Claim 100 (depends on 97) The method as claimed in claim 97, wherein n is 2 and R1 is on the carbon-3 position and the carbon-4 position of the phenyl group. ### Claim 101 (depends on 97) The method as claimed in claim 97, wherein n is 2 and each of R1 is —OH. ### Claim 102 (depends on 97) The method as claimed in claim 97, wherein p is 1. ### Claim 103 (depends on 97) The method as claimed in claim 97, wherein n is 3 to 5 and the remaining R1 is Z1T1, wherein Z1 is a sulfur (S) atom or oxygen (O) atom and T1 is a hydrogen or a lower alkyl group. ### Claim 104 (depends on 97) The method as claimed in claim 97, wherein T is an aliphatic group with 1 to 30 carbons. ### Claim 105 (depends on 97) The method as claimed in claim 97, wherein the aliphatic group of T is an alkyl. ### Claim 106 (depends on 97) The method as claimed in claim 97, wherein the nucleophile of R2 and/or R3 is selected from the group consisting of a halide, a nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile. ### Claim 107 (depends on 106) The method as claimed in claim 106, wherein the nitrogen nucleophile is an amino group. ### Claim 108 (depends on 107) The method as claimed in claim 107, wherein the amino group is selected from the group consisting of NH, NHV and NVV′ where V and V′ are each independently selected from the group consisting of a C1-C6 lower alkyl, a phenyl, and an alkoxy group. ### Claim 109 (depends on 97) The method as claimed in claim 97, wherein the compound is selected from the group consisting of: ### Claim 110 (depends on 97) The method as claimed in claim 97, wherein said patient in need of cell therapy has a condition selected from the group consisting of cancer, autoimmune disease, proliferative disorder, inflammatory disorder, neurological disorder, age-related disorder, allergic disorder, immune disorder, viral infection, burn, trauma, other conditions involving tissue injury, and other conditions wherein cell therapy is desirable. ### Claim 111 (depends on 97) A method for preventing dedifferentiation of differentiated cells, the method comprising administering an effective amount of a compound of the formula (I), or a pharmaceutically-acceptable salt thereof, as defined in claim 97. ### Claim 112 (depends on 111) The method of claim 111, wherein said dedifferentiation occurs in vivo after transplantation of said differentiated cells in a patient in need of cell therapy. ### Claim 113 (depends on 97) A method of enriching for a population of differentiated cells from a cell population comprising differentiated cells, undifferentiated stem cells or dedifferentiated stem cells, the method comprising the step of contacting said cell population with an effective amount of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof as defined in claim 97.